NDASUBLINGUALTABLET
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Data completeness
5/8 — Partial
Drug Shortage Active
NOCDURNA is currently in shortage. Reason: Unavailable. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
NOCDURNA (desmopressin acetate) by Ferring Pharmaceuticals is acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (v2) receptors. First approved in 2018.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOCDURNA (desmopressin acetate) is a sublingual tablet that acts as a vasopressin V2 receptor agonist to increase water reabsorption in the kidneys. It is indicated for nocturnal enuresis (nighttime bedwetting) in adults and children. The drug works by binding to V2 receptors in the renal collecting ducts, increasing urine concentration and reducing nighttime urine output.
$0.002BPart D
Peak3.8 years to LOEProduct is in peak revenue stage with modest Part D uptake (2,686 claims in 2023), suggesting stable but niche market presence with focused commercial team needs.
Mechanism of Action
acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
Started Jul 2021
1,099,551 enrolled
Adverse Drug Event
Desmopressin Acetate 0.2 mg Tablets, Fasting
Started Jul 2003
48 enrolled
Healthy
Why This Matters for Your Career
Worked on NOCDURNA at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.